Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26). This evidence concerns the gene JAK1 and peripheral T-cell lymphoma, not otherwise specified.